This is a preview of subscription content, log in via an institution to check access.
Notes
2016 US dollars
Reference
Dottino JA, et al. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstetrics and Gynecology : 11 Mar 2019. Available from: URL: http://doi.org/10.1097/AOG.0000000000003171
Rights and permissions
About this article
Cite this article
Niraparib not cost effective for platinum-sensitive ovarian cancer. PharmacoEcon Outcomes News 825, 25 (2019). https://doi.org/10.1007/s40274-019-5791-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5791-z